Bicyclic peptides exhibit improved metabolic stabilities, membrane permeabilities, and target specificities over their linear and mono-cyclic counterparts, however, efficient bicyclization remains ...

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary b ...

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each ...

BARCELONA, September 14, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ...

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, ...

Their patent portfolio consisted of “3 patent families directed to novel scaffolds and linkers, 10 patent families directed to our platform technology, 61 patent families directed to bicyclic ...

Work at DE Shaw Research LLC has led to the identification of bicyclic imide compounds acting as transient receptor potential cation channel subfamily A member 1 (TRPA1) antagonists. BioWorld Science ...

Bicycle's bicyclic peptide drug discovery platform is designed to produce drug candidates that have targeting properties like antibodies but are much smaller molecules, making manufacturing and ...

Alternatively, lycopene cyclase introduces β-ionone rings at each end of lycopene yielding monocyclic and bicyclic carotenes. β-carotene hydroxylases and β-carotene ketolases target the ionone ...

We are using dipolar cycloaddition chemistry to access a variety of alkaloid structures. Intramolecular cycloadditions provide an efficient means to build up bicyclic and polycyclic ring systems in a ...

The industry has been calling for a disease-agnostic event fully dedicated to the exciting new modality of peptide-based drugs. Here responding to this building momentum and demand in the space ...

EphA2-targeting BT5528 demonstrated an emerging differentiated safety profile and antitumor activity in patients with advanced solid tumors, including a 45% ORR in mUC 6.5 mg/m2 every two weeks ...